Breast cancer after chest radiation therapy for childhood cancer.

J Clin Oncol

Chaya S. Moskowitz, Joanne F. Chou, Suzanne L. Wolden, Jonine L. Bernstein, Danielle Novetsky Friedman, Nidha Z. Mubdi, Colin B. Begg, and Kevin C. Oeffinger, Memorial Sloan Kettering Cancer Center; Jyoti Malhotra, Mount Sinai Medical Center, New York, NY; Wendy M. Leisenring, Fred Hutchinson Cancer Research Center, Seattle, WA; Marilyn Stovall and Susan A. Smith, University of Texas MD Anderson Cancer Center, Houston, TX; Sue Hammond, Nationwide Children's Hospital, Columbus, OH; Tara O. Henderson, University of Chicago Medicine Comer Children's Hospital, Chicago, IL; John D. Boice, Vanderbilt-Ingram Cancer Center, Nashville; Melissa M. Hudson and Leslie L. Robison, St Jude Children's Research Hospital, Memphis, TN; Lisa R. Diller and Lisa B. Kenney, Dana-Farber Cancer Institute, Boston, MA; Smita Bhatia, City of Hope National Medical Center, Duarte, CA; and Joseph P. Neglia, University of Minnesota Masonic Cancer Center, Minneapolis, MN.

Published: July 2014

Purpose: The risk of breast cancer is high in women treated for a childhood cancer with chest irradiation. We sought to examine variations in risk resulting from irradiation field and radiation dose.

Patients And Methods: We evaluated cumulative breast cancer risk in 1,230 female childhood cancer survivors treated with chest irradiation who were participants in the CCSS (Childhood Cancer Survivor Study).

Results: Childhood cancer survivors treated with lower delivered doses of radiation (median, 14 Gy; range, 2 to 20 Gy) to a large volume (whole-lung field) had a high risk of breast cancer (standardized incidence ratio [SIR], 43.6; 95% CI, 27.2 to 70.3), as did survivors treated with high doses of delivered radiation (median, 40 Gy) to the mantle field (SIR, 24.2; 95% CI, 20.7 to 28.3). The cumulative incidence of breast cancer by age 50 years was 30% (95% CI, 25 to 34), with a 35% incidence among Hodgkin lymphoma survivors (95% CI, 29 to 40). Breast cancer-specific mortality at 5 and 10 years was 12% (95% CI, 8 to 18) and 19% (95% CI, 13 to 25), respectively.

Conclusion: Among women treated for childhood cancer with chest radiation therapy, those treated with whole-lung irradiation have a greater risk of breast cancer than previously recognized, demonstrating the importance of radiation volume. Importantly, mortality associated with breast cancer after childhood cancer is substantial.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4100937PMC
http://dx.doi.org/10.1200/JCO.2013.54.4601DOI Listing

Publication Analysis

Top Keywords

breast cancer
28
childhood cancer
28
cancer
13
cancer chest
12
risk breast
12
survivors treated
12
breast
8
chest radiation
8
radiation therapy
8
women treated
8

Similar Publications

Ultrasound-responsive nanoparticles for nitric oxide release to inhibit the growth of breast cancer.

Cancer Cell Int

December 2024

Department of Ultrasound, Chongqing General Hospital, Chongqing University, Chongqing, 401147, China.

Gas therapy represents a promising strategy for cancer treatment, with nitric oxide (NO) therapy showing particular potential in tumor therapy. However, ensuring sufficient production of NO remains a significant challenge. Leveraging ultrasound-responsive nanoparticles to promote the release of NO is an emerging way to solve this challenge.

View Article and Find Full Text PDF

Targeting CDK2 to circumvent treatment resistance in HR breast cancer.

Trends Mol Med

December 2024

Cancer Signaling and Microenvironment Program, Fox Chase Cancer Center, Philadelphia, PA, USA. Electronic address:

Genetic and epigenetic defects of the p53 system have previously been associated with resistance to CDK4/6 inhibitors in women with HR breast cancer. Recent data from Kudo et al. demonstrate that CDK2-targeting agents may offer an effective strategy to circumvent such resistance by enforcing cellular senescence downstream of RBL2 dephosphorylation.

View Article and Find Full Text PDF

Dabrafenib upregulates hypoglycosylated MUC1 and improves the therapeutic efficacy of Tn-MUC1 CAR-T cells.

Sci Bull (Beijing)

December 2024

Breast Cancer Center, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang 310022, China. Electronic address:

View Article and Find Full Text PDF

Computational Pathology Detection of Hypoxia-Induced Morphological Changes in Breast Cancer.

Am J Pathol

December 2024

Department of Computer Science, Faculty of Engineering Sciences, University College London, Gower Street, London, WC1E 6BT, United Kingdom.

Understanding the tumor hypoxic microenvironment is crucial for grasping tumor biology, clinical progression, and treatment responses. This study presents a novel application of AI in computational histopathology to evaluate hypoxia in breast cancer. Weakly Supervised Deep Learning (WSDL) models can accurately detect morphological changes associated with hypoxia in routine Hematoxylin and Eosin (H&E) whole slide images (WSI).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!